Logo

American Heart Association

  16
  0


Final ID: Su4011

The Artificial Intelligence-Derived Electrocardiographic Age Gap is Associated with Adverse Clinical Outcomes in Cardiac Laminopathy

Abstract Body (Do not enter title and authors here): Background: Disease-causative variants in LMNA-encoded lamin A/C cause the laminopathies, a heterogeneous group of diseases variably resulting in arrhythmogenic/dilated cardiomyopathy (ACM/DCM), lipodystrophy, muscular dystrophy, and progeria. The artificial intelligence (AI)-derived electrocardiographic age gap (AI-EAG), determined by the discrepancy between a patient’s artificial AI-enabled electrocardiogram (ECG) predicted biological age versus their chronological age, is accelerated in laminopathy. Thus, we sought to determine if the AI-EAG serves as a prognostic marker in patients with cardiac laminopathy.
Methods: Retrospective analysis of 1,049 genotype-positive patients with genetic ACM/DCM was used to identify those with pathogenic/likely pathogenic (P/LP) variants in LMNA. After the exclusion of those who lacked a 12-lead ECG while in sinus rhythm, a previously trained AI-ECG age algorithm was used to determine the AI-EAG by subtracting the patient’s chronological age from the AI-ECG derived biological age. The AI-EAG was then correlated with a combined outcome of major ventricular arrhythmia [sudden cardiac arrest, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator shocks], heart transplantation, and cardiovascular death.
Results: Overall, 147/1,049 (14%) patients with genetically-mediated ACM/DCM had a P/LP variant in LMNA. Of these, 80/147 (54%) LMNA variant-positive patients (52% female, mean chronological age 36 ± 15 years) had ECGs suitable for AI-EAG analysis. Most (52/80; 65%) had an AI-EAG >10 years with a mean AI-EAG of 17 ± 13 years. Of note, the AI-EAG was greater in those with a clinical cardiac phenotype (20 ± 14 vs. 13 ± 10 years; p = 0.011). As a continuous variable, an increased AI-EAG was associated with increased risk of the composite outcome at a median follow-up of 20 months (HR 1.036; 95% CI 1.004–1.068; p = 0.026) and AI-EAG > 10 and > 20 years were both associated with elevated risk (HR 4.272; 95% CI 1.388–13.147; p = 0.011 and HR 3.732; 95% CI 1.505–9.255; p = 0.004, respectively).
Conclusion: In cardiac laminopathy, an increased AI-EAG was common and correlated with adverse cardiovascular outcomes. Non-invasive ascertainment of electrocardiographic aging by AI may provide a novel prognostic marker in cardiac laminopathy. Future studies are needed to validate this finding and further define the role of the AI-EAG in the risk-stratification of patients with cardiac laminopathy.
  • Castrichini, Matteo  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Ackerman, Michael  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Milone, Margherita  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Giudicessi, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Sularz, Agata  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Garmany, Ramin  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Tester, David  ( MAYO CLINIC COLLEGE OF MEDICINE , Rochester , Minnesota , United States )
  • Bos, Johan  ( Mayo Clinic College of Medicine , Rochester , Minnesota , United States )
  • Attia, Zachi  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Noseworthy, Peter  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Friedman, Paul  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Lopez-jimenez, Francisco  ( MAYO CLINIC COLL MEDICINE , Rochester , Minnesota , United States )
  • Author Disclosures:
    Matteo Castrichini: DO NOT have relevant financial relationships | Michael Ackerman: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:UpToDate:Active (exists now) ; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Solid Biosciences:Active (exists now) ; Royalties/Patent Beneficiary:Prolaio:Active (exists now) ; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now) ; Royalties/Patent Beneficiary:AliveCor:Active (exists now) ; Consultant:Tenaya Therapeutics:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Invitae:Past (completed) ; Consultant:Illumina:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:BioMarin Pharmaceutical:Past (completed) | Margherita Milone: DO NOT have relevant financial relationships | John Giudicessi: DO have relevant financial relationships ; Consultant:Avidity Biosciences:Active (exists now) ; Consultant:Nuevocor Therapeutics:Active (exists now) ; Consultant:Citizen Health:Active (exists now) | Agata Sularz: DO NOT have relevant financial relationships | Ramin Garmany: DO NOT have relevant financial relationships | David Tester: No Answer | Johan Bos: DO NOT have relevant financial relationships | Zachi Attia: No Answer | Peter Noseworthy: DO have relevant financial relationships ; Royalties/Patent Beneficiary:Anumana:Active (exists now) | Paul Friedman: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Anumana:Active (exists now) ; Other (please indicate in the box next to the company name):Eko Health:Active (exists now) ; Other (please indicate in the box next to the company name):AliveCor:Active (exists now) | Francisco Lopez-Jimenez: DO have relevant financial relationships ; Advisor:Novo Nordisk:Active (exists now) ; Other (please indicate in the box next to the company name):Up-To-Date Author of chapter:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:WizeHealth:Past (completed) ; Royalties/Patent Beneficiary:Anumana:Active (exists now) ; Consultant:New Amsterdam Pharma:Past (completed) ; Consultant:MediWhale:Past (completed) ; Researcher:Select Research:Past (completed) ; Consultant:K-Health:Active (exists now) ; Consultant:Kento Health:Active (exists now) ; Advisor:Anumana:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Predicting and Treating Genetic Cardiomyopathies

Sunday, 11/09/2025 , 11:30AM - 12:30PM

Abstract Poster Board Session

More abstracts on this topic:
9-Year Longitudinal Assessment of the 12-lead Electrocardiogram of Volunteer Firefighters

Bae Alexander, Dzikowicz Dillon, Lai Chi-ju, Brunner Wendy, Krupa Nicole, Carey Mary, Tam Wai Cheong, Yu Yichen

Activin Type IIA Receptor Inhibition Decreases Atrial Fibrillation Inducibility In Mice Via a Smurf1-Connexin43 Mechanism

Castro Claire, Lee Se-jin, Ellinor Patrick, Rosenzweig Anthony, Roh Jason, Bapat Aneesh, Hobson Ryan, Yu Andy, Li Haobo, Xiao Chunyang, Xia Peng, Yeri Ashish, Yu Paul

More abstracts from these authors:
Electrocardiographic Aging in Genetic Cardiomyopathies: Insights from an Artificial Intelligence-Enabled Electrocardiogram Analysis

Sularz Agata, Ackerman Michael, Giudicessi John, Castrichini Matteo, Garmany Ramin, Bos Johan, Attia Zachi, Noseworthy Peter, Friedman Paul, Lopez-jimenez Francisco, Milone Margherita

Prevalence, Clinical Characteristics, and Outcomes of Patients with Genotype-Positive Arrhythmogenic Cardiomyopathy Presenting with a Sentinel Sudden Cardiac Arrest

Swain William, Garmany Ramin, Castrichini Matteo, Bos Johan, Neves Raquel, Ackerman Michael, Giudicessi John

You have to be authorized to contact abstract author. Please, Login
Not Available